AIMode.newsSearch
Live

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

N

Novartis

AIMode News Desk · curated summary

1 min readHealth

Automated news aggregation. Headlines and summaries are gathered from public feeds; see our editorial standards for sourcing, corrections, and AI-assist disclosure.

Related coverage: FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease Novartis

Advertisement

About this story

This story was aggregated from Novartis. Headlines, summaries, and links are gathered automatically from public RSS feeds for your convenience.

Read the full story →

More in Health

Health

New drug to treat one of the deadliest cancers is 'the real deal,' oncologist says

Related coverage: New drug to treat one of the deadliest cancers is 'the real deal,' oncologist says ksl.com Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer Nature Pancreatic Cancer Specialists Getting a Jump on Daraxonrasib Medscape Patients in Illinois starting to receive experimental pancreatic cancer drug: ‘Game changer’ Chicago Tribune Stanford expands access to revolutionary pancreatic cancer drug Stanford Medicine

ksl.com · 9 hours ago